Physician profile
Patrick Romeus
NPI 1669464335
$3,042.65
in general payments reported to CMS, 2019-2025
26 companies · $435 in 2025
The $435 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $489 · 2020: $432 · 2021: $314 · 2022: $254 · 2023: $510 · 2024: $609 · 2025: $435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,554.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,554.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $952.06 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $258.33 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $222.18 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $178.75 | 2023-2024 | Rexulti |
| Novartis Pharmaceuticals Corporation | $157.76 | 2019-2023 | |
| Amgen INC. | $138.52 | 2022-2025 | Repatha, Otezla, Krystexxa |
| Novo Nordisk INC | $122.24 | 2023-2025 | Rybelsus, Ozempic |
| Exact Sciences Corporation | $109.99 | 2023-2024 | Cologuard Collection Kit |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $107.14 | 2024-2025 | Caplyta |
| Lilly USA, LLC | $100.27 | 2019-2025 | Zepbound, Mounjaro |
| Pfizer INC. | $96.95 | 2022-2024 | |
| Glaxosmithkline, LLC. | $96.75 | 2022-2024 | Arexvy, Shingrix |
| Shield Therapeutics INC | $90.48 | 2023-2024 | Accrufer |
| Xeris Pharmaceuticals, INC. | $83.68 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $57.32 | 2019-2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $52.86 | 2021-2022 | |
| Gilead Sciences, INC. | $29.21 | 2025 | |
| Aurinia Pharma U.S., INC. | $27.80 | 2025 | Lupkynis |
| Horizon Therapeutics Plc | $22.40 | 2023 | Krystexxa |
| Viiv Healthcare Company | $21.59 | 2024 | Apretude |
| Dexcom, INC. | $20.44 | 2025 | Dexcom G6 Transmitter |
| Averitas Pharma INC. | $20.25 | 2024 | Qutenza |
| Abbott Laboratories | $19.77 | 2022 | |
| Sun Pharmaceutical Industries INC. | $19.72 | 2021 | |
| Lundbeck LLC | $18.10 | 2025 | Rexulti |
| Medtronic, INC. | $18.09 | 2025 | Minimed 780g |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Romeus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.